Single-Molecule Combinatorial Therapeutics for Treating Obesity and Diabetes
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
It will soon be 100 years since Frederick G. Banting, Charles Best, James Collip, and John J.R. Macleod in 1921 demonstrated that extracts of the pancreas had breathtaking beneficial effects to restore the health of patients with diabetes (1,2). While their breakthrough revolutionized the medical management of diabetes, the disease continues today to spread worldwide (3) along with a global increase in obesity. Novel unimolecular gut hormone polyagonists have shown unique potential to reverse obesity and diabetes in animal models and are currently being assessed in multiple clinical trials for their efficacy and safety (4). Insulin replacement therapy currently remains a central pillar of diabetes management while additional antidiabetes medicines enhance production, secretion, and action of insulin to improve disease management and enhance patient care. Enormous progress has been made in the precise and continuous quantification of blood glucose, which, together with next-generation insulin pumps, has enabled closed-loop delivery systems, a sizable step forward in the direction of automatized insulin therapy. The cure still remains elusive, and prevalence of the disease continues to rise across the globe, frighteningly so at an accelerated pace in some of the most populous countries. How can it be that a century after the discovery of insulin, the occurrence of disease is increasing with no cure to stem the epidemic in sight? The vast majority of diabetes worldwide is constituted of what was traditionally characterized as adult-onset, type 2 diabetes (T2D). This form of diabetes is clearly driven by another pandemic—that of obesity—and to an increasing extent is no longer an adult-onset disease. While the specific molecular mechanisms by which obesity is promoting the diabetes epidemic remain unclear, there is no controversy that in the absence of obesity, the magnitude of the diabetes problem would be far less significant and more manageable. …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity
Wahl, S., Drong, A., Lehne, B., Loh, M., Scott, W. R., Kunze, S., Tsai, P.-C., Ried, J. S., Zhang, W., Yang, Y., et al. (2017) · Nature · doi:10.1038/nature20784 · Cited by 945 · cited 1×
“Changes in histone code or DNA methylation patterns are frequently considered to be the basis of such epigenetic modifications (5).”
BackgroundUnimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 1×
“Such dual incretins, or twincretins, also exhibited metabolic profiles superior to those of monoagonists but differed significantly from those of glucagon-based drug candidates (15).”
Self-citationA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
Self-citationA new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Self-citationThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419 · cited 1×
“The first encouraging studies showed that comparably adding the nine–amino acid COOH-terminal tail that differentiates exendin from GLP-1 to glucagon provided a soluble, stable, and selective glucagon agonist that exemplified glucagon’s weight loss–inducing efficacy (11).”
BackgroundSelf-citationThe metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406
Self-citationBaggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372 · cited 1×
“The importance of glucagon action within a fully effective dual-agonist peptide is further exemplified by the gut peptide oxyntomodulin, which shows impotent in vivo metabolic effect that is GLP-1 receptor mediated (14).”
BackgroundFibroblast Growth Factor 21 Mediates Specific Glucagon Actions
Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., et al. (2013) · Diabetes · doi:10.2337/db12-1116 · Cited by 245
Self-citationFinan, B., Clemmensen, C., Zhu, Z., Stemmer, K., Gauthier, K., Müller, L., De Angelis, M., Moreth, K., Neff, F., Perez-Tilve, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.014 · Cited by 191
Self-citation
Cited by
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Marine Collagen as A Promising Biomaterial for Biomedical Applications
Lim, Y.-S., Ok, Y.-J., Hwang, S.-Y., Kwak, J.-Y., & Yoon, S. (2019) · Marine Drugs · doi:10.3390/md17080467 · Cited by 328
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Self-citationAdriaenssens, A., Broichhagen, J., de Bray, A., Ast, J., Hasib, A., Jones, B., Tomas, A., Burgos, N. F., Woodward, O., Lewis, J., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.164921 · Cited by 77
Psilopanagioti, A., Nikou, S., Logotheti, S., Arbi, M., Chartoumpekis, D. V., & Papadaki, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314899 · Cited by 22
“The essential molecular mechanisms underlying body weight gain remain largely unknown [46].”
BackgroundEvers, A., Pfeiffer‐Marek, S., Bossart, M., Elvert, R., Lorenz, K., Heubel, C., Garea, A. V., Schroeter, K., Riedel, J., Stock, U., et al. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000052 · Cited by 9
Metadata
- Authors
- Tschöp, M., & DiMarchi, R.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2017-06-15
- Volume
- 66
- Issue
- 7
- Pages
- 1766-1769
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2622944243
- Cited by
- 27
- References
- 9
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.